Amgen demonstrated resilience in Q1 2020 by achieving an 11% year-over-year revenue increase despite COVID-19 challenges. Management's confident outlook, strong cash flow, and strategic focus on adaptable product lines like Otezla suggest the stock may experience positive momentum in the short term.

[1]